COX-2 Blockade in Cancer Prevention and Therapy

  • Randall E. Harris

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-x
  2. Historical Perspectives

    1. Front Matter
      Pages 1-1
    2. Harvey R. Herschman
      Pages 13-32
  3. Epidemiology of NSAIDs and Cancer

    1. Front Matter
      Pages 33-33
  4. Animal Models of Carcinogenesis

  5. Molecular Biology of COX-2

    1. Front Matter
      Pages 157-157
    2. Rajnish A. Gupta, Raymond N. DuBois
      Pages 159-169
    3. Alane T. Koki, Kathleen M. Leahy, Janet M. Harmon, Jaime L. Masferrer
      Pages 185-203
    4. Jeanette A. Richards, Robert W. Brueggemeier
      Pages 205-224
    5. Linda C. Hsi, Thomas E. Eling
      Pages 245-255
  6. Clinical Applications

    1. Front Matter
      Pages 257-257
    2. Timothy Maziasz, K. Nasir Khan, John Talley, James Gierse, Karen Seibert
      Pages 259-277
    3. Gary J. Kelloff, Vernon E. Steele, Caroline C. Sigman
      Pages 279-300
    4. Randy Burd, Hak Choy, Adam Dicker
      Pages 301-311
    5. William F. Anderson, Asad Umar, Jaye L. Viner, Ernest T. Hawk
      Pages 313-340
  7. Back Matter
    Pages 367-371

About this book


The discovery that aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have notable antineoplastic properties has revolutionized cancer research. In COX-2 Blockade in Cancer Prevention and Therapy, a panel of leading experts chronicles the evidence for the chemopreventive and therapeutic effects of cyclooxygenase-2 (COX-2) inhibitors against virtually all forms of cancer and presents exciting new opportunities for the use of COX-2 blockade in their prevention and treatment. These highly experienced authors elucidate the process by which COX-2 inhibitors interrupt prostaglandin biosynthesis and cancer development, examine the positive epidemiological effects of such NSAIDs as aspirin and ibuprofen on various cancers, and demonstrate through animal models that NSAIDs inhibit a variety of malignant neoplasms in vivo. They also present genetic models confirming the critical role of COX-2 in carcinogenesis and discuss how its molecular biology modulates carcinogenesis via such processes as mutagenesis, cell division, angiogenesis, cell differentiation, and apoptosis. In addition, the authors review the clinical applications of selected NSAIDs that are immediately relevant to cancer prevention and control and outline the future prospects of COX-2 blocking agents.
Comprehensive and up-to-date, COX-2 Blockade in Cancer Prevention and Therapy demonstrates how COX-2 inhibitors and other NSAIDs reduce the risk of most cancers and provides cancer investigators today with a clear and authoritative guide to the development of novel agents with significant antineoplastic properties.


Prevention of breast cancer cancer prevention chemoprevention prevention prevention and control tumorigenesis

Editors and affiliations

  • Randall E. Harris
    • 1
  1. 1.The Ohio State University College of Medicine and School of Public HealthColumbusUSA

Bibliographic information